Breaking News Instant updates and real-time market news.

TIF

Tiffany

$89.85

-0.08 (-0.09%)

05:31
09/22/17
09/22
05:31
09/22/17
05:31

Tiffany downgraded to Neutral from Buy at Goldman Sachs

Goldman Sachs analyst Lindsay Drucker Mann downgraded Tiffany & Co. to Neutral and cut her price target for the shares to $94 from $106. The stock closed yesterday down 8c to $89.85. The company's high-end categories, including engagement, wedding and solitaire jewelry, decelerated in the last two quarters, Drucker Mann tells investors in a research note. Weakness in the high price point product categories could delay the timeline for a broader sales recovery at Tiffany, the analyst contends. She sees the valuation being "capped" without further sales improvement.

  • 03

    Oct

  • 04

    Oct

TIF Tiffany
$89.85

-0.08 (-0.09%)

05/24/17
COWN
05/24/17
NO CHANGE
Target $107
COWN
Outperform
Tiffany weakness a buying opportunity, says Cowen
Cowen analyst Oliver Chen noted Tiffany reported better than expected Q1 earnings however comps came in lower than expected. The analyst believes the Americas comp is likely volatile given changes in tourism flow, but mainland China was strong. He is a strong believer in the company's long-term prospects and as a result sees the weakness as a buying opportunity for long-term investors. Chen reiterated his Outperform rating and $107 price target on Tiffany shares.
06/27/17
BOFA
06/27/17
NO CHANGE
Target $110
BOFA
Buy
Tiffany added to US 1 List at BofA/Merrill
BofA/Merrill analyst Lorraine Hutchinson added Tiffany to the US 1 List and reiterated a Buy rating and $110 price target on shares. Hutchinson sees several catalysts leading to a 2017 turnaround including an increased pace of innovation by a new Head Designer, the shakeup in management and Board, and the "wealth effect" from the rising stock market. The analyst believes second half 2017 could see a comp inflection and said Tiffany is one of the few retailers with pricing power.
07/18/17
NEED
07/18/17
INITIATION
NEED
Hold
Tiffany initiated with a Hold at Needham
08/25/17
COWN
08/25/17
NO CHANGE
Target $102
COWN
Outperform
Tiffany positive comps expected to return in second half 2017, says Cowen
Cowen analyst Oliver Chen said Tiffany's Q2 results were solid and he expects positive comps to return in the second half of 2017, noting he sees opportunity from new products on existing platforms. He said increased unit growth across all regions, strong digital sales, and consumers responding to newness underscore his conviction in the shares. Chen reiterated his Outperform rating and $102 price target on Tiffany.

TODAY'S FREE FLY STORIES

GNRC

Generac

$50.49

-0.4 (-0.79%)

07:19
10/18/17
10/18
07:19
10/18/17
07:19
Recommendations
Generac analyst commentary  »

Generac estimates raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

ADP

ADP

$113.72

-0.86 (-0.75%)

07:19
10/18/17
10/18
07:19
10/18/17
07:19
Periodicals
Ackman increases pressure on ADP over tech development, WSJ reports »

Activist investor and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

PRKR

ParkerVision

$1.50

-0.06 (-3.85%)

07:19
10/18/17
10/18
07:19
10/18/17
07:19
Hot Stocks
ParkerVision enters common stock purchase agreement with Aspire Capital »

ParkerVision announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRO

GoPro

$9.23

0.15 (1.65%)

07:19
10/18/17
10/18
07:19
10/18/17
07:19
Technical Analysis
Technical View: GoPro trades higher, analyst action »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

NAVI

Navient

$12.20

0.47 (4.01%)

07:17
10/18/17
10/18
07:17
10/18/17
07:17
Hot Stocks
Navient sees adding over $1B of education refinance loans in FY17 »

Including the planned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Conference/Events
Commodity Futures Trading Commission Commissioners to speak at Expo »

Brian Quintenz and Rostin…

FGEN

FibroGen

$55.30

0.8 (1.47%)

, AZN

AstraZeneca

$34.78

0.13 (0.38%)

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Hot Stocks
FibroGen announces CFDA acceptance of roxadustat NDA »

FibroGen (FGEN) and its…

FGEN

FibroGen

$55.30

0.8 (1.47%)

AZN

AstraZeneca

$34.78

0.13 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 08

    Nov

  • 09

    Nov

CMG

Chipotle

$329.30

8.91 (2.78%)

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Technical Analysis
Technical View: Chipotle falls, analyst actions »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

UNH

UnitedHealth

$203.89

10.69 (5.53%)

, AMZN

Amazon.com

$1,009.13

2.79 (0.28%)

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Recommendations
UnitedHealth, Amazon.com analyst commentary  »

UnitedHealth price target…

UNH

UnitedHealth

$203.89

10.69 (5.53%)

AMZN

Amazon.com

$1,009.13

2.79 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 26

    Oct

  • 18

    Mar

AAN

Aaron's

$41.55

0.01 (0.02%)

07:15
10/18/17
10/18
07:15
10/18/17
07:15
Initiation
Aaron's initiated  »

Aaron's initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

BMTC

Bryn Mawr Bank

$44.50

-0.1 (-0.22%)

, FCF

First Commonwealth

$13.94

-0.26 (-1.83%)

07:13
10/18/17
10/18
07:13
10/18/17
07:13
Conference/Events
FDIC to hold a committee meeting »

The FDIC's Advisory…

BMTC

Bryn Mawr Bank

$44.50

-0.1 (-0.22%)

FCF

First Commonwealth

$13.94

-0.26 (-1.83%)

ONB

Old National Bancorp

$18.40

-0.05 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 24

    Oct

  • 25

    Oct

  • 06

    Nov

HCC

Warrior Met Coal

$24.04

0.51 (2.17%)

07:13
10/18/17
10/18
07:13
10/18/17
07:13
Downgrade
Warrior Met Coal rating change  »

Warrior Met Coal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOH

Molina Healthcare

$61.54

1.68 (2.81%)

, UNH

UnitedHealth

$203.89

10.69 (5.53%)

07:13
10/18/17
10/18
07:13
10/18/17
07:13
Periodicals
Health insurers prepare for enrollment drop amid ACA uncertainty, WSJ says »

As enrollment for 2018…

MOH

Molina Healthcare

$61.54

1.68 (2.81%)

UNH

UnitedHealth

$203.89

10.69 (5.53%)

CNC

Centene

$93.80

2.88 (3.17%)

WCG

WellCare

$174.03

6.11 (3.64%)

CI

Cigna

$187.20

2.21 (1.19%)

ANTM

Anthem

$187.26

3.5 (1.90%)

HNT

Health Net

HUM

Humana

$240.43

3.26 (1.37%)

AET

Aetna

$155.90

4.46 (2.95%)

EHTH

eHealth

$23.79

-0.61 (-2.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 31

    Oct

  • 31

    Oct

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

  • 14

    Dec

IBM

IBM

$146.54

-0.29 (-0.20%)

07:12
10/18/17
10/18
07:12
10/18/17
07:12
Recommendations
IBM analyst commentary  »

IBM reported 'best…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 15

    Nov

NVO

Novo Nordisk

$49.31

-0.01 (-0.02%)

07:12
10/18/17
10/18
07:12
10/18/17
07:12
Conference/Events
FDA Endocrinologic & Metabolic Drugs Advisory Committee to hold a meeting »

The Committee discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

TSLA

Tesla

$355.75

5.15 (1.47%)

07:11
10/18/17
10/18
07:11
10/18/17
07:11
Periodicals
Tesla employees claim dismissals not performance related, CNBC reports »

Tesla is trying to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

ATTU

Attunity

$6.90

0.12 (1.77%)

07:11
10/18/17
10/18
07:11
10/18/17
07:11
Hot Stocks
Attunity's Replicate adopted by large health insurance provider »

Attunity announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

MYGN

Myriad Genetics

$35.84

-0.26 (-0.72%)

07:10
10/18/17
10/18
07:10
10/18/17
07:10
Hot Stocks
Myriad Genetics BRACAnalysis CDx sPMA by FDA for review »

Myriad Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

MAIN

Main Street

$40.07

-0.1 (-0.25%)

07:09
10/18/17
10/18
07:09
10/18/17
07:09
Hot Stocks
Main Street announces semi-annual supplemental cash dividend of 27.5c per share »

Main Street Capital is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

JNJ

Johnson & Johnson

$140.79

4.67 (3.43%)

07:09
10/18/17
10/18
07:09
10/18/17
07:09
Recommendations
Johnson & Johnson analyst commentary  »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

IONS

Ionis Pharmaceuticals

$63.85

2.7 (4.42%)

07:09
10/18/17
10/18
07:09
10/18/17
07:09
Hot Stocks
Ionis collaborates with Seventh Sense Biosystems in blood collection device »

Ionis Pharmaceuticals has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 26

    Oct

LRCX

Lam Research

$194.55

2.19 (1.14%)

07:08
10/18/17
10/18
07:08
10/18/17
07:08
Recommendations
Lam Research analyst commentary  »

Lam Research price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMRN

Immuron

$5.03

0.1 (2.03%)

07:06
10/18/17
10/18
07:06
10/18/17
07:06
Initiation
Immuron initiated  »

Immuron initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLRX

BioLineRx

$1.09

-0.065 (-5.63%)

, RHHBY

Roche

$31.45

0.27 (0.87%)

07:05
10/18/17
10/18
07:05
10/18/17
07:05
Hot Stocks
BioLineRx: Genentech initiates Phase 1b/2 trial for BL-8040 »

BioLineRx (BLRX)…

BLRX

BioLineRx

$1.09

-0.065 (-5.63%)

RHHBY

Roche

$31.45

0.27 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

  • 30

    Nov

CEVA

CEVA

$45.40

0.1 (0.22%)

07:05
10/18/17
10/18
07:05
10/18/17
07:05
Hot Stocks
CEVA and Brodmann17 partner for deep learning in edge devices »

CEVA and Broadmann17, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.